Antibacterial Agents TRIZ Cases

Acrylamide derivatives inhibit the bacterial FabI enzyme to block fatty acid biosynthesis, addressing antibiotic resistance without harming mammalian cells.

Iminothiadiazine dioxide compounds modify the heterocyclic core structure to improve solution stability while maintaining potent beta-secretase 1 inhibition.

Selective Class II HDAC inhibition enhances Treg activity while avoiding side effects from non-selective broad-spectrum enzyme suppression.

Pyrimidine derivatives inhibit biofilm formation and treat resistant bacterial infections, addressing antibiotic resistance challenges.

Switching from water-based to organic solvent systems prevents disodium salt formation, improving cefsulodin sodium stability and purity.

Nitrogen heterocycle derivatives inhibit stearoyl-CoA desaturase-1 to treat obesity and type 2 diabetes by modulating fatty acid synthesis.

Specific bacteriophages penetrate bacterial biofilms to destroy antibiotic-resistant Pseudomonas aeruginosa strains.

Guanosine replaces alum adjuvants to activate Toll-like receptors, shifting immune responses from weak Th2 bias to robust Th1 protection.

Short peptides with specific amino acid sequences combat resistant bacteria and fungi while minimizing allergic reactions.

PlyPa91 lysin degrades peptidoglycan to treat multidrug-resistant Pseudomonas aeruginosa without antibiotic toxicity.

A pyridino-dioxapentacyclohenicosa-dione compound exhibits high antimicrobial activity against resistant bacteria and fungi.

A chimeric peptide combines alpha-synuclein and beta-amyloid sequences to bind GM1 and GM3 gangliosides with high affinity.

A lipid-based pre-formulation forms a non-lamellar liquid crystalline matrix upon contact with aqueous fluids.

Specific RNA ligands trigger TLR13 activation to treat bacterial infections resistant to standard antibiotics.

A press-coated tablet uses a swellable polymer layer to delay drug release for three to six hours before continuous administration.

Oritavancin achieves rapid bactericidal activity and sustained efficacy by maintaining a specific fraction bound to serum proteins.

P4 peptides amplify opsonic antibody activity to boost pathogen internalization by effector cells.

Benzimidazole-4-carboxamide derivatives enhance cancer therapy efficacy while minimizing toxicity through selective PARP inhibition.

Propylene glycol dissolves micronized mometasone in an oil-in-water emulsion, resolving poor solubility and improving bioavailability.

Vitamin E esters reduce biofilm production by 50-86% while maintaining skin tolerance against antimicrobial resistance.

Chromane amidine monobactams combat resistant Gram-negative bacteria by modifying molecular parameters to overcome beta-lactamase defenses.

Segmenting virulence factors into chimeric proteins resolves the complexity of expressing native conformations while maintaining high immunogenicity.

Hygromycin A compounds kill spirochetes to treat infections without disrupting the gut microbiome.

Diaminopyrimidine benzenesulfone derivatives bind bromodomain proteins to modulate transcriptional elongation.

Lactic acid bacterial composition adheres to gastric cells and inhibits Helicobacter pylori growth, offering a safe alternative to antibiotic triple therapy.

A minimized oligopeptide containing the RANKL DE loop sequence inhibits proinflammatory cytokine secretion from cells.

Anionic phthalocyanine compounds block RecA-mediated DNA repair, preventing bacterial resistance development during antibiotic treatment.

RNA vaccines encoding pertussis antigens elicit robust cellular immunity.

Recombinant CRISPR-Cas system utilizes Cascade complex and Cas3 polypeptide to target specific bacterial genomic sequences.

Macrocyclic compounds inhibit hepatitis C virus NS3 protease to overcome limited clinical benefits of existing interferon-based immunotherapy treatments.

Cationic steroid-polyamine conjugates condense plasmid DNA through electrostatic interactions to facilitate efficient gene delivery.

Optimized aryl urea compounds resolve complex signaling contradictions by selectively targeting FPRL-1 receptors to reduce tissue damage.

Cis-monounsaturated fatty acids dismantle biofilm matrices, restoring antibiotic susceptibility and reducing bacterial loads without increasing toxicity.

Aspergillomarasmine A chelates zinc ions in metallo-beta-lactamase active sites, restoring beta-lactam antibiotic efficacy against resistant bacteria.

Deleting UL49.5 and Us4 genes in BHV-1 vaccines removes immunosuppression, enabling effective co-administration with other antigens.

VHH polypeptides bind to Clostridium perfringens virulence factors, reducing necrotic enteritis severity without promoting antibiotic resistance.

Wolfberry milk composition delivers bioactive nutrients through a stabilized emulsion process.

Novel prenylated polyhydroxystilbene derivatives from propolis inhibit cancer cell growth and modulate SIRT1 enzyme activity.

Faecalibacterium prausnitzii and potato starch prevent Clostridium difficile colonization by reinforcing intestinal barriers during antibiotic therapy.

Novel quinolone compounds address the trade-off between enhanced anti-cancer efficacy and pharmaceutical usability through targeted structural modifications.

Modifying O-antigen chain length in engineered E. coli generates glycoconjugates that elicit robust bactericidal immune responses across multiple serotypes.

MG53 mediates damaged membrane repair by translocating to injury sites and facilitating vesicular fusion, addressing defects in tissue regeneration.

Immunomodulators mobilize neutrophils and activate immune responses, reducing antibiotic resistance risks in wound healing.